Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase-Reference-Cited by-同舟云学术

Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase

Published:2021-06 Issue:6 Volume:11 Page:1555-1567
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Li Quanjie,Yi Dongrong,Lei Xiaobo,Zhao Jianyuan,Zhang Yongxin,Cui Xiangling,Xiao Xia,Jiao Tao,Dong Xiaojing,Zhao Xuesen,Zeng Hui,Liang Chen,Ren Lili,Guo Fei^ORCID,Li Xiaoyu,Wang Jianwei,Cen Shan^ORCID

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference52 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou;Nature,2020

2. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2;Nat Microbiol,2020

3. First case of 2019 novel coronavirus in the United States;Holshue;N Engl J Med,2020

4. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, Peopleʹs Republic of China, in February, 2003;Zhong;Lancet,2003

5. Coronaviruses post-SARS: Update on replication and pathogenesis;Perlman;Nat Rev Microbiol,2009

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kaempferol as a novel inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase;Journal of Biomolecular Structure and Dynamics;2024-09-11

2. Utilization of the EpiMed Coronabank Chemical Collection to identify potential SARS-CoV-2 antivirals: in silico studies targeting the nsp14 ExoN domain and PLpro naphthalene binding site;Journal of Molecular Graphics and Modelling;2024-09

3. Recent advances in application of computer-aided drug design in anti-COVID-19 Virials Drug Discovery;Biomedicine & Pharmacotherapy;2024-04

4. Optimized Recombinant Expression and Purification of the SARS‐CoV‐2 Polymerase Complex;Current Protocols;2024-03

5. Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp;Biomedicine & Pharmacotherapy;2024-02